In short
Higher-dose intranasal delivery expanded for study participants with Parkinson's. The team continued to collect participant reports.
Most of February's update covered other topics, so the Parkinson's section was short.
The update said the team continued to see improvements among participants with Parkinson's.
It then explained how the research is set up. The work is a medical research study, meant to learn about FGF-1 and what it does in Parkinson's. There is no placebo group, meaning no group that receives an inactive substance for comparison.
As the team learned more each month, the update said, it had been able to give participants higher amounts of FGF-1 and had improved the way the protein is delivered through the nose. All participants receive the newest version of the dosing plan. The team reported seeing more improvement with these changes.
The update noted again that the brain imaging study at Washington University in St. Louis was continuing. The scans look at blood flow in the brain before and after FGF-1 dosing.
In closing, the chief executive listed Parkinson's and stroke recovery among the areas Zhittya was working on, alongside other research areas.
This summary covers the Parkinson's research in the February 2026 update. The complete update, including the other topics it covered, is below.
Read the complete February 2026 update as published
The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.